Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=23 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=72 Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Phase 2 N=16 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · Pancreatic Adenocarcinoma
Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants
Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 2 N=21 Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Primary: Progression-free Survival — 2 Participants
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=106 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=8 AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Phase 2 N=180 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.8; 9.8 months — p=0.72
Phase 2 N=39 Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 2 N=35 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Complete Response Rate — 21; 9; 2 Participants
Phase 2 N=54 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Phase 2 N=18 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Number of Patients Who Experienced a Dose-Limiting Toxicity (DLT) — 9; 8 participants
Phase 2 N=127 FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=204 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Primary: Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms — 38; 70; 5; 12 Participants — p==0.7158
Phase 2 N=104 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 4.2; 8.3 months — p=0.36
Phase 2 N=11 A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…
Phase 2 N=64 ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Phase 1: Number of Dose Limiting Toxicities — 3; 0; 0; 0 Dose Limiting Toxicities